ACTA and access to medicines

A study by Sean Flynn and Bijan Madhani, commissioned by the Greens/EFA Group

The Greens/EFA Group in the European Parliament commissioned this analysis of potential impacts of the Anti-Counterfeiting Trade Agreement (ACTA) on access to medicines in developing countries."

On the whole, ACTA negotiators created an agreement that shifts international "hard law" rules and "soft law" encouragements toward making enforcement of intellectual property rights in courts, at borders, by the government and by private parties easier, less costly, and more "deterrent" in the level of penalties.

In doing so, it increases the risks and consequences of wrongful searches, seizures, lawsuits and other enforcement actions for those relying on intellectual property limitations and exceptions to access markets, including the suppliers of legitimate generic medicines. This, in turn, is likely to make affordable medicines more scarce and dear in many countries. (...)

Recommended

Press release

https://unsplash.com/photos/gray-concrete-building-covered-trees-dqXiw7nCb9Q



EU adopts groundbreaking Corporate Sustainability Due ...

24.04.2024

Press release

https://www.greens-efa.eu/de/artikel/press/vote-on-eus-fiscal-rules-ignores-scars-of-financial-crisis-will-lead-to-more-austerity



MEPs adopt Ecodesign and Right to Repair Regulations

23.04.2024

News

European Union




Plenary Flash 22 - 25 April 2024

19.04.2024

Study

© Christoph Diewald | Flickr



Alternatives for a fair and sustainable partnership be...

17.04.2024

Responsible MEPs



Jan Philipp Albrecht

Member

Contact person



Jan Philipp Albrecht

Member	

Attached documents

ACTA and access to medicines

Please share

<u>E-Mail</u>